RECOMBINANT VACCINIA CEA (70DD) VACCINE IN LOW TUMOR BURDEN COLORECTAL CANCER

这项研究的目的是评估一种改良的天花病毒的有效性，这种病毒已经被操纵来携带癌胚抗原(CEA)基因。这种分子在大多数结肠腺癌中都有表达。推测免疫系统会对牛痘-CEA(70kD)疫苗产生类似于抗天花免疫反应的强烈的抗CEA反应。这种基因工程疫苗已经在动物身上进行了测试，发现是安全有效的。对其他疾病类型也启动了类似的疫苗接种战略，没有观察到意外反应。这项试验将评估副作用以及对疫苗的反应。疫苗接种计划包括两个独立的疫苗接种，相隔八周。患者将接受第一次疫苗接种，作为皮内应用疫苗，使用标准的划痕技术。他们将被跟踪8周。如果没有副作用，可以考虑接种强化疫苗。这项研究将在门诊基础上进行。

The purpose of this study is to evaluate the effectiveness of a modified form of the smallpox virus which has been manipulated to carry the gene for carcinoembryonic antigen (CEA). This molecule is expressed by a majority of adenocarcinomas of the colon. The supposition is that the immune system will respond to the vaccinia-CEA (70 Kd) vaccine causing a strong anti-CEA response similar to the anti smallpox immune response. This genetically engineered vaccine has been tested in animals and found to be safe and effective. Similar vaccination strategy has been initiated for other disease types and no unexpected reactions have been observed. This trial will evaluate the side effects as well as the response to the vaccine. The vaccination program consists of two separate vaccinations eight weeks apart. Patients will receive the first vaccination as an intradermal application of the vaccine using a standard scarification technique. They will be followed for eight weeks. If there are no side effects a booster vaccination will be admnistered. This study will be conducted on an outpatient basis.